tbuckley/cabot-search huggingface dataset:
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Authors: Cyra Patel, Julia ML Brotherton, Alexis Pillsbury, Sanjay Jayasinghe, Basil Donovan, Kristine Macartney, Helen Marshall
Journal: Eurosurveillance (2018)

Background: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. Aim: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine. Methods: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden. Results: Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible women have been observed. Reductions in genital warts incidence and HPV prevalence among heterosexual men of similar age were observed before introduction of the male vaccination programme, indicating a substantial herd effect. 9vHPV vaccine is expected to prevent up to 90% of cervical and 96% of anal cancers. Of an estimated 1,544 HPV-associated cancers in 2012, 1,242 would have been preventable by the 4vHPV vaccine and an additional 187 anogenital cancers by the 9vHPV vaccine. Conclusions: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.
Abstract 14628: Angiotensin II Type 1 Receptor Autoantibody Prolonged Angiotensin II Type 1 Receptor Activation Through Attenuating Receptor Internalization in Cultured Vascular Smooth Muscle Cells
Authors: Jinghui Lei, Suli Zhang, Jingwei Bian, Xiaochen Yin, Peng Wang, Pengli Wang, Ye Wu, Huirong Liu
Journal: Circulation (2016)

Introduction: Angiotensin II type 1 receptor autoantibody (AT1-AA) can persistently activate angiotensin II type 1 receptor (AT1R), thereby has pathogenetic relevance to hypertension, but the exact...
Two-session endoscopic purse-string suture to close a huge esophagojejunal anastomosis thoracic cavity fistula
Authors: Wei Wang, Ke Qi, Xusheng Chang, Zhendong Jin, Zhaoshen Li
Journal: Endoscopy (2018)

Esophageal anastomosis leaks or fistulas are life-threatening conditions after surgery and have high morbidity and mortality. Traditionally, neither surgical repair nor conservative therapy could improve the prognosis effectively. In recent years, endoscopic methods, such as using esophageal stents, OverStitch (Apollo Endosurgery, Austin, Texas, USA), and the Over-the-Scope Clip system (Ovesco Endoscopy AG, Tübingen, Germany), have been an effective alternative to surgery [1] [2] [3]. However, it remains a challenge to endoscopically close huge fistulas, especially those larger than 30 mm. We report the method of endoscopic purse-string suture with clips and endoloops for the closure of a huge esophagojejunal anastomosis fistula [4].
Association Between Unintentional Child Injury in the Home and Parental Implementation of Modifications for Safety
Authors: Vanya C. Jones, Wendy Shields, Rajiv Ayyagari, Shannon Frattaroli, Eileen M. McDonald, Andrea C. Gielen
Journal: JAMA Pediatrics (2018)

This study of pediatric emergency department medical records explores children’s unintentional home injuries and parents’ reports of the cause of the injury, what could have prevented it, and changes made in homes afterward.
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Authors: Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Andrew Hill, David Hogg, Ivan Marquez-Rodas, Joel Jiang, Jasmine Rizzo, James Larkin, Jedd D Wolchok
Journal: The Lancet Oncology (2018)
Loss of Gut Microbiota Alters Immune System Composition and Cripples Postinfarction Cardiac Repair
Authors: Tony W.H. Tang, Hung-Chih Chen, Chen-Yun Chen, Christopher Y.T. Yen, Chen-Ju Lin, Ray P. Prajnamitra, Li-Lun Chen, Shu-Chian Ruan, Jen-Hao Lin, Po-Ju Lin, Hsueh-Han Lu, Chiung-Wen Kuo, Cindy M. Chang, Alexander D. Hall, Eugenio I. Vivas, Jr-Wen Shui, Peilin Chen, Timothy A. Hacker, Federico E. Rey, Timothy J. Kamp, Patrick C.H. Hsieh
Journal: Circulation (2019)

The impact of gut microbiota on the regulation of host physiology has recently garnered considerable attention, particularly in key areas such as the immune system and metabolism. These areas are also crucial for the pathophysiology of and repair after myocardial infarction (MI). However, the role of the gut microbiota in the context of MI remains to be fully elucidated. To investigate the effects of gut microbiota on cardiac repair after MI, C57BL/6J mice were treated with antibiotics 7 days before MI to deplete mouse gut microbiota. Flow cytometry was applied to examine the changes in immune cell composition in the heart. 16S rDNA sequencing was conducted as a readout for changes in gut microbial composition. Short-chain fatty acid (SCFA) species altered after antibiotic treatment were identified by high-performance liquid chromatography. Fecal reconstitution, transplantation of monocytes, or dietary SCFA or Lactobacillus probiotic supplementation was conducted to evaluate the cardioprotective effects of microbiota on the mice after MI. Antibiotic-treated mice displayed drastic, dose-dependent mortality after MI. We observed an association between the gut microbiota depletion and significant reductions in the proportion of myeloid cells and SCFAs, more specifically acetate, butyrate, and propionate. Infiltration of CX3CR1+ monocytes to the peri-infarct zone after MI was also reduced, suggesting impairment of repair after MI. Accordingly, the physiological status and survival of mice were significantly improved after fecal reconstitution, transplantation of monocytes, or dietary SCFA supplementation. MI was associated with a reorganization of the gut microbial community such as a reduction in Lactobacillus. Supplementing antibiotic-treated mice with a Lactobacillus probiotic before MI restored myeloid cell proportions, yielded cardioprotective effects, and shifted the balance of SCFAs toward propionate. Gut microbiota-derived SCFAs play an important role in maintaining host immune composition and repair capacity after MI. This suggests that manipulation of these elements may provide opportunities to modulate pathological outcome after MI and indeed human health and disease as a whole.
Phase 1 study on safety and PK of rovalpituzumab tesirine (Rova-T) in Japanese patients with advanced, recurrent SCLC
Authors: Kentaro Tanaka, Hibiki Udagawa, Hiroaki Akamatsu, Masayuki Takeda, Shintaro Kanda, Ikuko Yasuda, Sumiko Okubo, Shekman Wong, Charity Scripture, Tomohide Tamura, Isamu Okamoto
Journal: Annals of Oncology (2018)
GW29-e1593 Difference in Long-term Cerebrovascular Embolism risk between Sustained Atrial Fibrillation and Paroxysmal Atrial Fibrillation: A Systemic Review and Meta-analysis
Authors: Yang Sun, Daobo Li, Gary Tse, Tong Liu, Yunlong Xia
Journal: Journal of the American College of Cardiology (2018)
Abstract 20223: Deep Proteome Analysis Identified Complete Secretome as the Functional Unit of Human Cardiac Progenitor Cells
Authors: Sudhish Sharma, Rachana Mishra, Grace E Bigham, Brody P Wehman, Mohd M Khan, Srinivasa Raju Datla, Progyaparamita Saha, Young A Goo, Ling Chen, David R Goodlett, Sunjay Kaushal
Journal: Circulation (2016)

This investigation determines how chronological age influences the phenotypic characteristics and the secretome of human c-kit+ cardiac progenitor cells (CPCs) when comparing adult CPCs (aCPCs, age...
First-attempt success of emergency intubation with bougie was higher than with endotracheal tube plus stylet
Authors: Marilyn E. Innes
Journal: Annals of Internal Medicine (2018)

Source Citation Driver BE, Prekker ME, Klein LR, et al. Effect of use of a bougie vs endotracheal tube and stylet on first-attempt intubation success among patients with difficult airways undergoing emergency intubation: a randomized clinical trial. JAMA. 2018;319:2179-89. 29800096
P3.CR-31 A Case of Thymoma with Autoimmune Hepatitis Following Preoperative Chemotherapy
Authors: T. Nishimura, H. Tsunezuka, N. Miyata, S. Okada, S. Ishihara, S. Ikebe, H. Suzuki, C. Nakazono, N. Ishikawa, A. Uchibori, D. Kato, J. Shimada, M. Inoue
Journal: Journal of Thoracic Oncology (2018)
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
Authors: N.H.B. Schräder, J.C. Duipmans, B. Molenbuur, A.P. Wolff, M.F. Jonkman
Journal: British Journal of Dermatology (2018)

Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care‐based interventions. Opioid‐based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid‐based medicines (CBMs) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB. We present three patients with EB who were prescribed pharmaceutical‐grade sublingually administered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.
Cryptic severe Plasmodium falciparum malaria in a Moroccan man living in Tuscany, Italy, August 2018
Authors: Lorenzo Zammarchi, Nicoletta Di Lauria, Filippo Bartalesi, Lorenzo Roberto Suardi, Giampaolo Corti, Jessica Mencarini, Daniela Boccolini, Carlo Severini, Luigi Gradoni, Carla Buonamici, Giorgio Garofalo, Anna Maria Bartolesi, Nunziata Ciccone, Andrea Berni, Loredana Poggesi, Fabrizio Niccolini, Gian Maria Rossolini, Roberto Romi, Alessandro Bartoloni
Journal: Eurosurveillance (2018)

In August 2018 a Moroccan man living in Tuscany developed Plasmodium falciparum malaria. The patient declared having not recently visited any endemic country, leading to diagnostic delay and severe malaria. As susceptibility to P. falciparum of Anopheles species in Tuscany is very low, and other risk factors for acquiring malaria could not be completely excluded, the case remains cryptic, similar to other P. falciparum malaria cases previously reported in African individuals living in Apulia in 2017.
Calcipotriol-assisted vs. conventional MAL-PDT in actinic keratosis
Authors: L. Torezan, B. Grinblat, M. Haedersdal, N. Valente, C. Festa-Neto, R.M. Szeimies
Journal: British Journal of Dermatology (2018)

Actinic keratosis (AK) is a common pre‐malignant lesion (affected patch) of the skin that affects many people worldwide, especially fair skin type people. It is more common after the age of 40 and in sun‐exposed areas of the body. It can progress into a type of skin cancer named squamous cell carcinoma (SCC). For this reason, an adequate treatment of each AK lesion is recommended. This study aimed to treat these lesions with photodynamic therapy (PDT), which is a well‐established option. Normally, topical PDT is a treatment that combines a drug (applied to the lesions) and illumination with light (blue or red). The final result is the massive killing of the cancer cells that will bring high cure rates to these patients. However, AKs on the scalp are sometimes hard to treat and the efficacy levels are lower when compared to facial lesions. Therefore, we aimed to find if the combination of PDT with a well‐known drug named Calcipotriol would bring any benefit to the patients. So we compared: one half of the scalp with CAL and PDT and the other half with PDT alone. Patients were then followed (monitored) for 3 months. We found that the combination was safe and more effective for AK treatment, especially when the lesions were thicker. Side effects were more common, but well‐tolerated by the patients. This is the first study of CAL and PDT for AKs.
Observation of Moderately Dysplastic Nevi With Positive Margins
Authors: Adewole S. Adamson, Kelly C. Nelson
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Authors: Marine F. Garrido, Nicolas J.-P. Martin, Matthieu Bertrand, Catherine Gaudin, Frédéric Commo, Nassif El Kalaany, Nader Al Nakouzi, Ladan Fazli, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Daniel Compagno, Martin Gleave, Yohann Loriot, Laurent Désaubry, Stéphan Vagner, Karim Fizazi, Anne Chauchereau
Journal: Clinical Cancer Research (2018)

Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets for overcoming chemoresistance.Experimental Design: We established 4 chemoresistant prostate cancer cell lines and used image-based high-content siRNA functional screening, based on gene-expression signature, to explore mechanisms of chemoresistance and identify new potential targets with potential roles in taxane resistance. The functional role of a new target was assessed by in vitro and in vivo silencing, and mass spectrometry analysis was used to identify its downstream effectors.We identified FKBP7, a prolyl-peptidyl isomerase overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. This is the first study to characterize the function of human FKBP7 and explore its role in cancer. We discovered that FKBP7 was upregulated in human prostate cancers and its expression correlated with the recurrence observed in patients receiving docetaxel. FKBP7 silencing showed that FKBP7 is required to maintain the growth of chemoresistant cell lines and chemoresistant tumors in mice. Mass spectrometry analysis revealed that FKBP7 interacts with eIF4G, a component of the eIF4F translation initiation complex, to mediate the survival of chemoresistant cells. Using small-molecule inhibitors of eIF4A, the RNA helicase component of eIF4F, we were able to kill docetaxel- and cabazitaxel-resistant cells.Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.
Taxane &amp; cyclophosphamide vs anthracycline &amp; taxane combination therapy as adjuvant treatment of breast cancer: A meta-analysis of randomized-controlled trials by the Hellenic Academy of Oncology (E.AK.O.)
Authors: P. Ntellas, N. Spathas, D. Zylis, S. Agelaki, E. Zintzaras, E. Saloustros
Journal: Annals of Oncology (2018)
Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma
Authors: K.L. Kurzinski, C.K. Zigler, K.S. Torok
Journal: British Journal of Dermatology (2018)

Localized scleroderma (LS) is an autoimmune condition of the skin and underlying tissue. Active or recurring disease can lead to cumulative tissue damage, especially in paediatric-onset disease.To highlight the rate of relapse of LS activity in a cohort of paediatric patients and to evaluate for potential clinical and laboratory predictors of disease relapse.Clinical and laboratory data were gathered prospectively. Patients were categorized as experiencing relapse or not, and clinical and laboratory parameters were compared. A logistic regression was fit to predict odds of relapse while controlling for multiple predictors. A subgroup of patients was also evaluated to determine the average time from treatment completion to relapse.Seventy-seven patients were followed for the identified study duration of > 2 years and had achieved disease remission, with 35 (45%) experiencing LS relapse. Patients who were older at disease onset, antinuclear antibody (ANA) positive and without an extracutaneous manifestation (ECM) were more likely to relapse. All three variables remained significant in the multivariable logistic regression model. Results of the subgroup mirrored the larger sample. The average time between treatment completion and relapse was 21 months.Assessment of patients with LS experiencing a relapse of disease activity has shown older age of initial LS onset and ANA positivity to be potential markers for risk of relapse. Patients meeting these parameters may require greater clinical vigilance. The presence of one or more ECM may be protective. Clinicians treating patients with LS should provide significant long-term follow-up to monitor for relapse.
Two‐Layered and Stretchable e‐Textile Patches for Wearable Healthcare Electronics
Authors: Thanh‐Giang La, Shide Qiu, Dylan K. Scott, Reyhaneh Bakhtiari, Jonathan W. P. Kuziek, Kyle E. Mathewson, Jana Rieger, Hyun‐Joong Chung
Journal: Advanced Healthcare Materials (2018)

Wearable healthcare systems require skin-adhering electrodes that allow maximal comfort for patients as well as an electronics system to enable signal processing and transmittance. Textile-based electronics, known as "e-textiles," is a platform technology that allows comfort for patients. Here, two-layered e-textile patches are designed by controlled permeation of Ag-particle/fluoropolymer composite ink into a porous textile. The permeated ink forms a cladding onto the nanofibers in the textile substrate, which is beneficial for mechanical and electrical properties of the e-textile. The printed e-textile features conductivity of ≈3200 S cm-1 , whereas 1000 cycles of 30% uniaxial stretching causes the resistance to increase only by a factor of ≈5, which is acceptable in many applications. Controlling over the penetration depth enables a two-layer design of the e-textile, where the sensing electrodes and the conducting traces are printed in the opposite sides of the substrate. The formation of vertical interconnected access is remarkably simple as an injection from a syringe. With the custom-developed electronic circuits, a surface electromyography system with wireless data transmission is demonstrated. Furthermore, the dry e-textile patch collects electroencephalography with comparable signal quality to commercial gel electrodes. It is anticipated that the two-layered e-textiles will be effective in healthcare and sports applications.
Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment
Authors: Benjamin Planquette, Olivier Sanchez, James J. Marsh, Peter G. Chiles, Joseph Emmerich, Grégoire Le Gal, Guy Meyer, Tanya Wolfson, Anthony C. Gamst, Roger E. Moore, Gabriel B. Gugiu, Timothy A. Morris
Journal: European Respiratory Journal (2018)

Residual pulmonary vascular obstruction (RPVO) and chronic thromboembolic pulmonary hypertension (CTEPH) are both long-term complications of acute pulmonary embolism, but it is unknown whether RPVO can be predicted by variants of fibrinogen associated with CTEPH. We used the Akaike information criterion to select the best predictive models for RPVO in two prospectively followed cohorts of acute pulmonary embolism patients, using as candidate variables the extent of the initial obstruction, clinical characteristics and fibrinogen-related data. We measured the selected models’ goodness of fit by analysis of deviance and compared models using the Chi-squared test. RPVO occurred in 29 (28.4%) out of 102 subjects in the first cohort and 46 (25.3%) out of 182 subjects in the second. The best-fit predictive model derived in the first cohort (p=0.0002) and validated in the second cohort (p=0.0005) implicated fibrinogen Bβ-chain monosialylation in the development of RPVO. When the derivation procedure excluded clinical characteristics, fibrinogen Bβ-chain monosialylation remained a predictor of RPVO in the best-fit predictive model (p=0.00003). Excluding fibrinogen characteristics worsened the predictive model (p=0.03). Fibrinogen Bβ-chain monosialylation, a common structural attribute of fibrin, helped predict RPVO after acute pulmonary embolism. Fibrin structure may contribute to the risk of developing RPVO.
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Authors: James RW Conway, David Herrmann, TR Jeffry Evans, Jennifer P Morton, Paul Timpson
Journal: Gut (2018)

Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly solid tumours. This is due to a generally late-stage diagnosis of a primarily treatment-refractory disease. Several large-scale sequencing and mass spectrometry approaches have identified key drivers of this disease and in doing so highlighted the vast heterogeneity of lower frequency mutations that make clinical trials of targeted agents in unselected patients increasingly futile. There is a clear need for improved biomarkers to guide effective targeted therapies, with biomarker-driven clinical trials for personalised medicine becoming increasingly common in several cancers. Interestingly, many of the aberrant signalling pathways in PDAC rely on downstream signal transduction through the mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K) pathways, which has led to the development of several approaches to target these key regulators, primarily as combination therapies. The following review discusses the trend of PDAC therapy towards molecular subtyping for biomarker-driven personalised therapies, highlighting the key pathways under investigation and their relationship to the PI3K pathway.